申请人:Sumitomo Chemical Company, Limited
公开号:US03980645A1
公开(公告)日:1976-09-14
Fused quinazolinone derivatives of the formula, ##SPC1## Wherein R.sub.1 and R.sub.2 are individually hydrogen, C.sub.1.sub.-4 alkyl, C.sub.1.sub.-4 alkoxy, nitro, C.sub.1.sub.-4 alkylsulfonyl or halogen; R.sub.3 is pyridyl, thienyl or a group of the formula ##SPC2## Wherein R.sub. 4 is hydrogen or halogen; R is hydrogen, C.sub.1.sub.-4 alkyl, C.sub.2.sub.-5 alkenyl, aralkyl, (C.sub.3.sub.-6 cycloalkyl)C.sub.1.sub.-4 alkyl, (C.sub.1.sub.-4 alkoxy)C.sub.1.sub.-4 alkyl, (C.sub.1.sub.-4 alkylthio)C.sub.1.sub.-4 alkyl, hydroxy-C.sub.1.sub.-4 alkyl or C.sub.2.sub.-5 alkanoyloxy-C.sub.1.sub.-4 alkyl; Y is oxygen, or a group of the formula N - R.sub.5, wherein R.sub.5 is hydrogen or C.sub.1.sub.-4 alkyl; and Z is C.sub.2.sub.-5 alkylene or alkenylene, are prepared by reacting a trihaloacetamidophenyl ketone derivative of the formula, ##SPC3## Wherein R.sub.1, R.sub.2, R.sub. 3 and R are as defined above; and X.sub.1, X.sub.2 and X.sub.3 are halogen, with an amine of the formula, HY - Z - NH.sub.2, wherein Y and Z are as defined above, or a salt thereof, in the presence of a solvent or a mixture thereof. They have remarkable pharmacological properties such as anti-inflammatory, analgesic and/or uricosuric activities.
公式为 ##
SPC1## 的融合
喹唑啉酮衍
生物,其中 R.sub.1 和 R.sub.2 分别为氢、C.sub.1.sub.-4 烷基、C.sub.1.sub.-4 烷氧基、硝基、C.sub.1.sub.-4 烷基磺酰基或卤素;R.sub.3 为
吡啶基、
噻吩基或公式 ##
SPC2## 中的基团,其中 R.sub.4 为氢或卤素;R 为氢、C.sub.1.sub.-4 烷基、C.sub.2.sub.-5 烯基、苯基甲基、(C.sub.3.sub.-6 环烷基)C.sub.1.sub.-4 烷基、(C.sub.1.sub.-4 烷氧基)C.sub.1.sub.-4 烷基、(C.sub.1.sub.-4 烷基
硫基)C.sub.1.sub.-4 烷基、羟基-C.sub.1.sub.-4 烷基或 C.sub.2.sub.-5 酰氧基-C.sub.1.sub.-4 烷基;Y 为氧或公式 N-R.sub.5 的基团,其中 R.sub.5 为氢或 C.sub.1.sub.-4 烷基;Z 为 C.sub.2.sub.-5 烷基或烯基。通过在溶剂或混合物存在下,将公式为 ##
SPC3## 的三卤乙酰胺基苯酮衍
生物,其中 R.sub.1、R.sub.2、R.sub.3 和 R 如上所定义;X.sub.1、X.sub.2 和 X.sub.3 为卤素,与公式 HY-Z-NH.sub.2 的胺或其盐反应制备。它们具有显著的药理特性,如抗炎、镇痛和/或
利尿酸活性。